Peter Svennilson has worked in venture capital and finance for the past 28 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and was the Chairman of Seragon Pharmaceuticals until it was sold to Genentech in 2014. He is a Board Director of NGM Biopharmaceuticals and Immune Design.
Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Fiveprime. Prior to Three Crowns Capital he was the Associate Managing Director in charge of European Investment Banking Origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton.
Board of Directors: Immune Design, NGM Biopharmaceuticals